1. Genetic Polymorphism Of Cyp3A5 As A Key Regulator Of Pharmacokinetics Of Tacrolimus In Kidney Transplant Patients: Evidence In Kazakh Population

Authors

  • B.B. Baimakhanov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • A.T. Chormanov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • U.Sh. Medeubekov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • Zh.M. Syrymov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • I.K. Madadov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • K.S. Dabyltaeva JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • E.B. Belgibaev JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • E.S. Nabiev JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • N.T. Saduakas JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • A.Zh. Baiyz JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • B.R. Aipov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan

Downloads

Abstract

Immunosuppressive therapy with the use of tacrolimus is one of the main ones in kidney transplantation. The survival and maintenance of satisfactory graft function in a technically perfect operation depends in most cases on immunological factors. At the same time, there is a question of a personal approach to im-munosuppressive therapy of kidney recipients in patients of the Kazakh population before and after surgery. The genetic polymorphism of CYP3A5 is an important link affecting the concentration of tacrolimus and potentially able to predict the optimal dosage of tacrolimus in kidney recipients in the Kazakh population We examined 80 kidney recipients for the presence of CYP3A5 genetic polymorphism. All the pa-tients studied were selected from the ethnic population. Out of the total number of recipients: 37-men and 43-women. The median age was 37±8 years. All the studied patients underwent a related kidney transplant. The induction was performed using basilixamab or anti-thymocytic globulin (ATG). Immunesupressive regi-men was Tacrolimus + Mycophenolic acid + corticosteroids. Postoperatively tacrolimus concentration was taken at 2, 5, 7, 10 and 14th day after the surgery.

Keywords

tacrolimus, kidney transplantation, genetic polymorphism

References

  1. Oetting WS, Schladt DP, Guan W, Miller MB, Remmel RP., et al. DeKAF Investigators. (2016) Genomewide As-sociation Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Mul-tiple CYP3A5 Alleles. Am J Transplant. 16(2): 574-582
  2. Lucy Chen and G. V. Ramesh Prasad (2018) CYP3A5 polymorphisms in renal transplant recipients: influ-ence on tacrolimus treatment Pharmgenomics Pers Med. 11: 23–33
  3. Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A., et al. (2008) Influence of CYP3A5Genetic Poly-morphism on Tacrolimus Daily Dose Requirements and Acute Rejection in Renal Graft Recipients. Basic & Clini-cal Pharmacology & Toxicology. 103(6): 546–552
  4. Rojas L, Neumann I, Herrero MJ, Bosó V, Reig J., et al. (2015); Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic re-view and meta-analysis of observational studies. Pharmacogenomics J. 15(1): 38-48
  5. Sakaeda T, Nakamura T, Okumura K. (2003) Pharma-cogenetics of MDR1 and its impact on the pharmaco-kinetics and pharmacodynamics of drugs. Pharma-cogenomics. 4(4): 397-410
  6. Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L. (2013) Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene. 512(2): 226-231
  7. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genaz-zani AA. (2012) The effect of CYP3A5 6986A> G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal trans-plant patients: a systematic review and meta-analysis. Pharmacogenet Genomics. 22(8): 642-645
  8. Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS. (2005) Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Trans-plant. 19(6): 638-643

Published

2021-05-21

Issue

No. 1 (2021)

Section

Статьи